• If you are trying to figure out whether BeOne Medicines is attractively priced or already reflects its potential, you are in the right place.
• The stock closed at US$352.23, with a 7 day return of a 0.6% decline, a 30 day return of 4.8%, and longer term returns of 13.2% year to date, 26.5% over 1 year, 46.6% over 3 years and 21.8% over 5 years.
• These mixed short term and longer term returns often prompt investors to look more closely at what might be driving sentiment and expectations. In this article, we focus on valuation to help you interpret those moves in the context of BeOne Medicines current price.
• On Simply Wall St's 6 point valuation checklist, BeOne Medicines scores a 5 out of 6. This suggests several metrics flag the stock as undervalued. Next, we will compare different valuation approaches, then finish with a more complete way to think about what the company might be worth.

Approach 1: BeOne Medicines Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model projects a company’s future cash flows and then discounts them back to today’s value to estimate what the business might be worth now.

For BeOne Medicines, the model used is a 2 Stage Free Cash Flow to Equity approach. The latest twelve month free cash flow (FCF) is about $66.3 million. Analysts provide explicit FCF estimates for the next few years, and Simply Wall St then extends those projections further. By 2030, the projected FCF is $3,048.3 million, and there are additional extrapolated figures out to 2035, all expressed in US$.

Discounting this stream of projected cash flows results in an estimated intrinsic value of about $908.81 per share. Compared with the recent share price of $352.23, this implies an intrinsic discount of 61.2%. According to this model, the stock is assessed as undervalued.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests BeOne Medicines is undervalued by 61.2%. Track this in your watchlist or portfolio, or discover 53 more high quality undervalued stocks.

Approach 2: BeOne Medicines Price vs Sales

For a business like BeOne Medicines, where investors often care about revenue potential as much as current profits, the P/S ratio is a useful way to think about what you are paying for each dollar of sales.

Growth expectations and risk usually influence what feels like a reasonable P/S multiple. Higher growth or perceived quality can support a higher multiple, while more uncertainty or weaker margins often point to a lower one.

BeOne Medicines currently trades on a P/S of 7.84x. That sits below the Biotechs industry average P/S of 12.48x and below the peer group average of 21.40x. On the face of it, this suggests the market is pricing the company’s revenue below both the sector and its closer comparables.

Simply Wall St’s Fair Ratio for BeOne Medicines is 11.06x. This is a proprietary estimate of what the P/S might be given factors such as earnings growth, risk profile, profit margins, industry and market cap. Because it blends these company specific inputs, it can be more tailored than a simple comparison to broad industry or peer averages.

With the current P/S of 7.84x sitting below the Fair Ratio of 11.06x, the P/S multiple indicates that the stock may be undervalued on this basis.

Result: UNDERVALUED

P/S ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 21 top founder-led companies.

Upgrade Your Decision Making: Choose your BeOne Medicines Narrative

Earlier we mentioned that there is an even better way to think about valuation, and on Simply Wall St that is through Narratives. You set out your story for BeOne Medicines, link it to specific assumptions for future revenue, earnings and margins, and the platform converts that story into a forecast and a Fair Value that you can compare with the current price. This allows you to judge whether it looks high or low, all within the Community page that millions of investors use. As new information such as earnings or trial news is added, those Narratives update so you can see, for example, how a cautious view that aligns with a US$250 price target and assumes earnings of US$191.7m by 2028 differs from a more optimistic view that lines up with a US$563 price target and assumes earnings of US$2.7b by 2028. This gives you a clear, easy way to decide which story you agree with.

For BeOne Medicines however we will make it really easy for you with previews of two leading BeOne Medicines Narratives:

First up is the optimistic view, which leans into the idea that the market is underestimating the earnings power of the hematology and oncology portfolio.

Fair Value: US$507.57 per share

Implied discount vs last close: about 30.6% below this fair value estimate

Assumed revenue growth: 25.62% a year

• Sees BRUKINSA, sonrotoclax and the broader hematology and solid tumor portfolio supporting a larger, more profitable business over time.
• Builds in a move from losses to strong profitability, with higher net margins and a P/E multiple of 23.98x on future earnings.
• Argues that aging demographics, international expansion and a broad late stage pipeline are not fully reflected in today’s price.

Now here is the more cautious take, focused on what happens if execution or pricing power fall short of current optimism.

Fair Value: US$307.71 per share

Implied premium vs last close: about 14.5% above this fair value estimate

Assumed revenue growth: 14.26% a year

• Emphasizes reliance on BRUKINSA, potential patent and competition pressures, and the risk that pipeline expectations are set too high.
• Assumes more modest profitability, with a lower net margin profile but still a high implied future P/E multiple of 46.09x on earnings.
• Flags pricing pressure, regulatory scrutiny and the possibility that sentiment around the sector cools as key reasons the current price could be ahead of itself.

If you want to see how other investors are weighing these trade offs and where your own view sits, Curious how numbers become stories that shape markets? Explore Community Narratives can help you test your assumptions against both the bullish and bearish cases.

Do you think there's more to the story for BeOne Medicines? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.